October 02, 2015.
Teva (Petah Tikva, Israel) has entered into an agreement to acquire Mexican pharma company Representaciones e Investigaciones Médicas (Rimsa) for $2.3 billion, according to Streetinsider.com.
Rimsa, which had a 2014 revenue of $227 million, has a portfolio of specialty products, including fixed-dose combination products. The company has a 45-year history as one of Mexico's companies; Mexico is the second largest healthcare market in Latin America.
Teva expects to close the transactions by Q1 2016.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.